CaafimaadkaCudurada iyo Xaaladaha

Cudurka fayraska infakshanka papilomo: marka ay lagama maarmaan tahay

Papillomavirus-ka dadku waa arrin aad u caadi ah, dadka ugu badan ee adduunka ah ayaa ah kuwa sidooda ah. Xaaladaha intooda badan, fayruskan ma khatar galin karo siduu yahay, calaamadaheeda keliya waxay noqon kartaa mid ka baxsan maqaarka mid ka mid ah ama mid kale oo ku yaal qaybo kala duwan oo jirka ah. Waxay caadi ahaan u muuqdaan kaliya wakhti gaaban ka dib marka infekshanka ka dib uu dhakhso u gudbo, laakiin waxay mar kale ku dhici karaan hoos u dhac difaac ah. Mararka qaar infekshanku wuxuu noqon karaa asymptomatic.

Xaaladaha intooda badan, daaweynta infekshanka fayruska ee papillomato looma baahna, midkuna wuxuu ku wareegi karaa daaweynta ciladaha, taas oo ah, ka saarista burooyinka, laakiin qaar ka mid ah noocyada ay u badan tahay waxay u badan tahay inay keenaan kansar, ka dibna daaweynta antiviral waa mid aad u fiican. Ugu horreyntii, waxay ku saabsan tahay ciladaha papillomavirus ee lagu kala qaado galmada, kuwaas oo laba ka mid ah. Maadaama fayrasyadani ay sababi karaan cudur sida kansarka ilma-mareenka, tirada dadka aadka u badan ee raadinaya daaweynta fayruska waa haween. Si kastaba ha ahaatee, daaweynta caabuqa fayruska papilomo wuxuu u baahan yahay in la fuliyo oo keliya maaha, laakiin sidoo kale lammaanahooda, maadaama ay hubaal tahay in sidoo kale laga heli doono baaritaanka, iyo, inay noqdaan kuwo sidayaal ah, waxay dhab ahaantii ku soo laaban doonaan lammaanahooda.

Khaas ahaan khatarta waa xaaladda xilliga uurka: Mabda 'ahaan, uur-qaadida fayraska uur-qaadida iyo papilomo - ma jirto wax cabsi-gelin ah, laakiin kaliya haddii uusan haweenku qabin burooyinka xubinta taranka. Haddii ay yihiin, markaa khatarta u gudbinta infekshanka ilmaha inta lagu jiro dhalashada waa weyn yahay, iyo maskaxda neefsashada ilmaha iyo xubnaha taranka ayaa laga yaabaa inay saameyso. Inta aad uurka leedahay, khatarta dhacdooyinkooda waa weyn tahay, maadaama hoos u dhigis la'aanta haweeneyda. Daaweynta papilloma jeermiska fayraska xilliga uurka ma noqon karaan sabab u tahay xaqiiqda ah in marka uu helo daroogada xoog leh anti-viral in waxyeelayn kara ilmaha. Xaaladaha muhiimka ah, daaweyntu waa suurtogal kaddib 28 toddobaad oo uur ah, marka ilmuhu horay u sameeyay xubnaha jirka, wax badanna ma suura galin inay waxyeello u geystaan. Xaaladaha intooda badan, daaweynta cudurka fayraska papilloma xilliga uurka aan sameeyey, laakiin waxaa loo magacaabay by nidaamka si ay u soo saarto burooyinka ka soo marinka dhalmada.

Ka hor intaan la daaweyn, infekshanka fayraska Papilomo waa in la kala duwo, sababtoo ah inta badan noocyada caafimaad ee bani'aadamku maaha mid halis ah, iyo daroogooyinka ugu xoogga badan, ee lid ku ah, waxay dhaawici karaan jirka. Waxaa lagugula talinayaa in lagu daaweeyo noocyada oncogenic oo keliya. Sidoo kale, daaweynta infakshanka papillomavirus wuxuu dhici karaa marka qof u sababo hal sabab ama mid kale loo diido difaac, iyo jiritaanka xitaa infakshanka yar ee jirku uu noqon karo culeys xad-dhaaf ah isaga, tusaale ahaan, AIDS ama raajo shucaac, iyo sidoo kale tiro Cudurada qaaxada iyo xilliga baxnaaninta kadib hawlo adag.

Currently, waxaa jira tallaalka waxtar u leh ka hortaga oncogenic caabuqa HPV. Dalal badan, tallaalkan waxaa lagu daray liiska khasabka ah ee gabdhaha da'da dugsiga sare. Waxay si aan rasmi ahayn loogu yeeray tallaalka ka hortagga kansarka ilma-mareenka, waxaana jira sababo macquul ah. Aad ayey muhiim u tahay in tallaal noocan oo kale ah la sameeyo ka hor bilawga hawsha galmada, haddii kale waxay noqon doontaa wax aan faa'iido lahayn - haddii infekshanku horey ugu jirey jirka. Xaaladdan, waa in aad marka hore qaadato koorso daaweyn liddi ku ah fayras, ka dibna markaa ka dibna kicin tani. Wadankayaga, tallaal noocan oo kale ah ayaa wali lagu sameeyaa saldhig lacageed, laakiin mustaqbalka waxaa laga yaabaa in lagu daro liiska adeegyada uu caymiska caymiska caafimaadka.

Similar articles

 

 

 

 

Trending Now

 

 

 

 

Newest

Copyright © 2018 so.delachieve.com. Theme powered by WordPress.